| アブストラクト | This descriptive epidemiological study suggests that sequential osteoporosis therapy after denosumab discontinuation is underutilized in real-world practice. Within 1 year after discontinuation, approximately 30% of patients restarted denosumab, approximately half had no subsequent osteoporosis treatment, and only 16% initiated sequential osteoporosis therapy. PURPOSE: To describe real-world treatment patterns following denosumab discontinuation, including delayed reinitiation, no subsequent osteoporosis treatment, and sequential osteoporosis therapy. METHODS: This descriptive epidemiological study used a Japanese claims database (April 2014-March 2024). We included adults aged >/=40 years who newly initiated denosumab and discontinued it after >/=2 doses. Discontinuation was defined as the last administration before a gap of >240 days or final observed administration followed by >/=240 days without another administration. The primary outcomes within 1 year after discontinuation were delayed denosumab reinitiation, no subsequent osteoporosis treatment, and sequential osteoporosis therapy. We also described the type and timing of sequential therapy and estimated the 1-year cumulative incidence of fragility fractures. RESULTS: Among 37,526 eligible patients, the 1-year cumulative incidence of delayed denosumab reinitiation was 29.6%, the probability of no subsequent osteoporosis treatment was 50.9%, and the cumulative incidence of sequential osteoporosis therapy was 16.3%. Oral bisphosphonates were the most frequently used sequential therapy (26.7%), followed by romosozumab (22.2%), selective estrogen receptor modulators (21.3%), intravenous bisphosphonates (15.1%), teriparatide (14.6%), and abaloparatide (0.1%). Sequential therapy was most often initiated 180-209 days after discontinuation, particularly for romosozumab (45.7%), whereas selective estrogen receptor modulators were frequently initiated 0-29 days after discontinuation (39.8%). The 1-year cumulative incidence of fragility fractures was 5.4%. CONCLUSIONS: Within 1 year after discontinuation, approximately 30% of patients restarted denosumab, half received no subsequent osteoporosis treatment, and one in six initiated sequential therapy. These findings suggest a substantial gap in the continuity of osteoporosis care. |
| ジャーナル名 | Archives of osteoporosis |
| Pubmed追加日 | 2026/11/12 |
| 投稿者 | Yoshiyama, Takaki; Fukasawa, Toshiki; Masuda, Soichiro; Matsuda, Shuichi; Kawakami, Koji |
| 組織名 | Department of Pharmacoepidemiology, Graduate School of Medicine and Public;Health, Kyoto University, Kyoto, Japan.;Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University,;Kyoto, Japan.;Health, Kyoto University, Kyoto, Japan. fukasawa.toshiki.4a@kyoto-u.ac.jp.;Department of Orthopaedic Surgery, Kyoto City Hospital, Kyoto, Japan. |
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/43018839/ |